

Understanding the Impact of COVID-19 on the Care of Patients with Chronic Lymphocytic Leukemia

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- 1. Acalabrutinib may result in fewer of the toxicities commonly associated with ibrutinib, but it is noteworthy for the occurrence of which of the following adverse events during the first month of treatment?**
 - a. Hair loss
 - b. Headache**
 - c. Constipation
 - d. Visual disturbances
- 2. How are Bruton tyrosine kinase (BTK) inhibitors being investigated for patients with cancer who are infected with the novel coronavirus?**
 - a. As a direct therapy for COVID-19
 - b. As a potential treatment for COVID-19-related pulmonary damage**
- 3. The Phase II CALAVI study is evaluating the efficacy and safety of best supportive care with and without which of the following BTK inhibitors for patients hospitalized with COVID-19?**
 - a. Acalabrutinib**
 - b. Ibrutinib
 - c. Umbralisib
- 4. Preliminary results from a Phase III trial evaluating standard therapy with and without the investigational antiviral agent remdesivir for hospitalized patients with moderate COVID-19 pneumonia demonstrated an improvement with remdesivir in which endpoint?**
 - a. Duration of symptoms only**
 - b. Overall survival only
 - c. Duration of symptoms and overall survival